Hemostat

Visualizing Market Trends in Wound Care Management: COVID-19 Impact on Topical Absorbable Hemostats - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023
Medical Supplies, Health, Investment, COVID-19, Obstetrics, History, ASP, Burn, Bleeding, Equity, Strategic planning, Market, Hemostat, Gelatin, Trauma, CMO, Cellulose, SWOT analysis, Hemostasis, Collagen, SWOT, Forecast, Retail, Pharmaceutical industry, Health care, Video game, Risk management, Marketing

This report delves into the profound impact of COVID-19 on the Topical Absorbable Hemostats market in 2020 and beyond.

Key Points: 
  • This report delves into the profound impact of COVID-19 on the Topical Absorbable Hemostats market in 2020 and beyond.
  • Topical Absorbable Hemostatic agents, also referred to as passive hemostats, incorporate absorbable materials like collagen, gelatin, polysaccharide, oxidized regenerated cellulose, and combination hemostats.
  • Market Revenue Analysis: Explore the annualized total Topical Absorbable Hemostats market revenue by segment and market outlooks from 2015 to 2033.
  • Key Benefits of the Model:
    COVID-19 Impact Assessment: Understand the impact of COVID-19 on the Topical Absorbable Hemostats market.

Global Biosurgery Market Report to 2027 - Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022
Surgery, Health, Plastic surgery, Prostate cancer, Cancer, Infection, Sealant, Stroke, Pain, Competitive landscape, COVID-19, General surgery, Adhesion, Hospital, Baxter International, Acquisition, Coronary artery disease, Growth, Wound healing, Integra, British Heart Foundation, Bleeding, Degenerative disease, RTI, BD, Pfizer, Incidence, RTI Surgical, Retail, Beauty salon, Dietary supplement, Dentistry, Maggot therapy, Hemostat, Geography

The "Biosurgery - Global Market Insights, Competitive Landscape and, Market Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosurgery - Global Market Insights, Competitive Landscape and, Market Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global biosurgery market can be anticipated to grow at a CAGR of 9.23% during the forecast period of 2022-2027.
  • Key Takeaways from the Biosurgery Market Report Study:
    The effect of the COVID-19 pandemic on this market is significant.
  • To capture and analyze suitable indicators, our experts are closely watching the biosurgery market
    Key companies dominating the global biosurgery market.

Preclinical Evaluation of Tricol Biomedical’s Absorbable Biocompatible Chitosan (ABC) Wound Dressing Demonstrates Bioabsorption and Biocompatability in Internal Bleeding

Retrieved on: 
Thursday, September 29, 2022
Health, Hemostat, Development, FDA, Army of the United States, Kinetics, NOT, OR, Partnership, Patient, Trauma, INTERNAL, DE, ABC, US, Research, GLOBE, Injury, Hospital, Bleeding, Chitosan, Death, Silk, Medical device

Quickly accessing and stabilizing the wound with effective hemostatic techniques is the key for life saving in these events.

Key Points: 
  • Quickly accessing and stabilizing the wound with effective hemostatic techniques is the key for life saving in these events.
  • The results of the preclinical study demonstrated:
    Desirable bioabsorption properties and biocompatibility of the ABC dressing in both subcutaneous and intraperitoneal implantation models.
  • The ABC chitosan dressing demonstrates absorbable biocompatibility without systemic or local adverse responses.
  • The ABC chitosan dressing does not result in surgical adhesion formation greater than Grade 2 no surgical adhesions were observed.

The Worldwide Hemostats Industry is Expected to Reach $2.6+ Billion in 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 25, 2022
Medical Devices, Health, Death, Ministry, World, Blood, Patient, Logistics Management Institute, International Labour Organization, Bleeding, Hospital, Crash, Investment, Kidney, Growth, Union, Man, Insurance, Woman, World Health Organization, Accident, Transport, Insurance Institute for Highway Safety, Pharmaceutical industry, Medical device, Hemostat, Eurostat, Highway

Increased focus on blood loss management will also lead to the growth of the Hemostats market during the given forecast period.

Key Points: 
  • Increased focus on blood loss management will also lead to the growth of the Hemostats market during the given forecast period.
  • Growth in the number of hospitals and surgical centers across the globe will further require Hemostats for blood loss management, thus, boosting the market for Hemostats.
  • The growing number of accidents leading to the surgery requirement will also support the Hemostats market.
  • The market is expected to surge in the coming years, due to the rising number of accidents, worldwide.

Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio

Retrieved on: 
Thursday, July 29, 2021
Medical devices, Health, Hospitals, Surgery, Clinical trials, Pharmaceutical, Medicine, Health sciences, Health care, Medical terminology, Antihemorrhagic, Shaving, Transfusion medicine, Hematology, Adhesion barrier, Hemostasis, Topical medication, Hemostat

PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.

Key Points: 
  • PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.
  • The trial evaluated the safety and efficacy of PerClot in achieving intraoperative hemostasis compared to the control (a similar marketed hemostatic powder).
  • Combined use of PerClot PHS with other topical hemostatic agents has not been studied in controlled clinical trials.
  • This release includes forward-looking statements concerning a definitive agreement entered into by Baxter to acquire PerClot Polysaccharide Hemostatic System from CryoLife, including expectations regarding the financial impact and other benefits of such acquisition for Baxter.

GATT announces first-in-man use of 'GATT-Patch', a hemostatic sealant patch, by Radboud university medical center Nijmegen

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Transfusion medicine, Clinical medicine, Medicine, Antihemorrhagic, Shaving, Hemostat, Radboud University Nijmegen, Radboud University Medical Center, Bleeding, Hepatectomy, Radbod

b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).

Key Points: 
  • b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).
  • Having fast and effective solutions to manage complex bleeding is crucial to prevent complications for patients during or after surgery.
  • Hemostats and sealants are used when other methods to contain the bleeding are ineffective or insufficient.
  • Stuart Head, Chief Medical Officer of GATT, commented: "Principal investigators Professor dr. de Wilt (Radboudumc), Professor dr. Porte (University Medical Center Groningen), and Professor dr. Verhoef (Erasmus Medical Center) and their teams are a fantastic group to work with.

GATT announces first-in-man use of 'GATT-Patch', a hemostatic sealant patch, by Radboud university medical center Nijmegen

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Transfusion medicine, Clinical medicine, Medicine, Antihemorrhagic, Shaving, Hemostat, Radboud University Nijmegen, Radboud University Medical Center, Bleeding, Hepatectomy, Radbod

b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).

Key Points: 
  • b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).
  • Having fast and effective solutions to manage complex bleeding is crucial to prevent complications for patients during or after surgery.
  • Hemostats and sealants are used when other methods to contain the bleeding are ineffective or insufficient.
  • Stuart Head, Chief Medical Officer of GATT, commented: "Principal investigators Professor dr. de Wilt (Radboudumc), Professor dr. Porte (University Medical Center Groningen), and Professor dr. Verhoef (Erasmus Medical Center) and their teams are a fantastic group to work with.

Hemostats and tissue sealants market to grow by USD 1.50 billion during 2021-2025|Key Vendor Insights and Forecasts| Technavio

Retrieved on: 
Thursday, March 4, 2021
Materials, Sealant, Dental sealant, Hemostat

NEW YORK, March 4, 2021 /PRNewswire/ -- The global hemostats and tissue sealants market is expected to grow by USD 1.50 billion during 2021-2025, as per Technavio.

Key Points: 
  • NEW YORK, March 4, 2021 /PRNewswire/ -- The global hemostats and tissue sealants market is expected to grow by USD 1.50 billion during 2021-2025, as per Technavio.
  • Download Free Sample Report in Minutes
    Read the 120-page report with TOC on "Hemostats and Tissue Sealants Market Analysis Report by Product (Hemostats, Tissue sealants and adhesives, and Fibrin sealants) and Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts,2021-2025".
  • https://www.technavio.com/report/report/hemostats-and-tissue-sealants-ma...
    The hemostats and tissue sealants market is driven by the use of hemostats and tissue sealants in surgeries.
  • Hemostats And Tissue Sealants Market Product Outlook (Revenue, USD billion, 2020-2025)
    Hemostats And Tissue Sealants Market Geography Outlook (Revenue, USD billion, 2020-2025)
    Are you a start-up willing to make it big in the business?

FDA Approves EndoClot® Hemostat to Manage GI Bleeding

Retrieved on: 
Tuesday, February 23, 2021
Biotechnology, FDA, Surgery, Medical devices, Health, Antihemorrhagic, Shaving, Transfusion medicine, Starch, Hemostat, Health, Branches of biology, Medical specialties

EndoClot Plus, Inc. (EPI) announced the U.S. Food and Drug Administration (FDA) has approved EndoClot Polysaccharide Hemostatic System (EndoClot PHS), an innovative product that assists Gastroenterologists to stop bleeding rapidly and reliably.

Key Points: 
  • EndoClot Plus, Inc. (EPI) announced the U.S. Food and Drug Administration (FDA) has approved EndoClot Polysaccharide Hemostatic System (EndoClot PHS), an innovative product that assists Gastroenterologists to stop bleeding rapidly and reliably.
  • EndoClot PHS is a single use device including a starch-based powder hemostat that is applied directly to the bleeding site through a flexible endoscope.
  • The FDA clearance of EndoClot PHS represents a significant milestone in advancing the care of the GI patient.
  • EndoClot Plus Co., Ltd. located in Suzhou, China is the manufacturer of the EndoClot product lines including EndoClot PHS, EndoClot Adhesive and EndoClot Submucosal Injection System.

Medtech Companies in Flowable Hemostats Market Cement Supply Chains to Ensure Access to Advanced Hemostatis for Surgeries, Valuation to Reach US$1 Bn by 2027: TMR

Retrieved on: 
Thursday, January 21, 2021
Transfusion medicine, Hemostat, Antihemorrhagic, Medical specialties, Flowable, Tranexamic acid, Clinical medicine, Branches of biology

The sales in the flowable hemostats market has risen due the widespread application of these in general surgeries.

Key Points: 
  • The sales in the flowable hemostats market has risen due the widespread application of these in general surgeries.
  • Some of the product categories in the flowable hemostats market that exhibit vast clinical promise are tranexamic acid-loaded starch microspheres and thrombin-gelatin hemostatic matrix.
  • The valuation in the global flowable hemostats market was pegged at US$ 700 Mn in 2018, and is anticipated to reach worth of US$1 bn by 2027-end.
  • Analysts at TMR concur that in recent months, medical technology companies in the flowable hemostats market are consolidating their production capabilities to develop hemostats used in vascular surgeries.